FindTrial
Sign In

B1962

DRUG3 trials

Sponsors

Tasly Biopharmaceuticals Co., Ltd.

Conditions

Advanced Colorectal CancerCervical CancersColorectal CancerHepatocellular Carcinoma (HCC)Neoplasms MalignantNon-Squamous Non-Small Cell Lung CancerRecurrent Platinum-resistant Epithelial Ovarian CancerSmall Cell Lung Cancer

Phase 1

A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors
NCT05650385
Tasly Biopharmaceuticals Co., Ltd.Neoplasms Malignant
Start: 2022-12-31End: 2025-10-31Target: 68Updated: 2022-12-14

Phase 2

A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
Not yet recruitingNCT06724263
Tasly Biopharmaceuticals Co., Ltd.Cervical Cancers, Colorectal Cancer, Hepatocellular Carcinoma (HCC) +4
Start: 2024-12-31End: 2026-08-31Target: 120Updated: 2024-12-09
A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer
Not yet recruitingNCT06838546
Tasly Biopharmaceuticals Co., Ltd.Advanced Colorectal Cancer
Start: 2025-02-24End: 2027-01-31Target: 80Updated: 2025-02-20